Semaglutide vs Tirzepatide vs Retatrutide: Side Effects

    By Trimi Medical Team14 min read

    All GLP-1 medications share a similar core side effect profile (primarily gastrointestinal), but the severity, duration, and specific effects differ between semaglutide, tirzepatide, and retatrutide. Understanding these differences helps you choose the medication most likely to be tolerable for your body.

    Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Side effects vary significantly between individuals. Report any concerning symptoms to your healthcare provider immediately.

    Side Effect Comparison Table

    Side EffectSemaglutideTirzepatideRetatrutide
    Nausea40-45%35-40%40-50%
    Vomiting15-20%10-15%15-20%
    Diarrhea25-30%15-20%25-30%
    Constipation15-20%15-20%15-20%
    Increased Heart RateMinimalMinimalModerate (glucagon)
    Feeling Warm/HotUncommonUncommonCommon (thermogenesis)
    Hair ThinningRelated to weight loss rateModerate-HighHigher
    Discontinuation Rate~5-7%~3-5%~5-8%

    Key Differences Explained

    Semaglutide: The Most-Studied Profile

    Semaglutide has the most long-term safety data (15+ years for the GLP-1 class). Its side effects are well-characterized and predominantly gastrointestinal. Most side effects improve within 4-8 weeks of each dose increase. Nausea tends to be worst during the first few days after each injection.

    Tirzepatide: Generally Best Tolerated

    Despite producing more weight loss, tirzepatide tends to have slightly lower nausea and vomiting rates than semaglutide in head-to-head comparisons. The GIP component may have a buffering effect on GLP-1-related nausea. Tirzepatide has the lowest discontinuation rate due to side effects among the three medications.

    Retatrutide: Unique Glucagon Effects

    Retatrutide's glucagon receptor activation introduces side effects not seen with semaglutide or tirzepatide. The increased thermogenesis can make patients feel warm or slightly flushed. A modest increase in resting heart rate (3-5 bpm) is common. GI side effects are comparable to semaglutide but with the added complexity of three-receptor activation.

    Managing Side Effects: Universal Strategies

    • Eat slowly and smaller portions: The most effective nausea prevention
    • Stay hydrated: Dehydration worsens every side effect
    • Ginger supplements: Clinically proven for GLP-1-related nausea
    • Titrate gradually: Do not rush dose increases
    • Time injections strategically: Some patients do better injecting in the evening

    Choose Your Best Fit with Trimi

    Trimi's medical team helps match you with the right medication for your tolerability. Compounded semaglutide is $99/month and compounded tirzepatide is $125/month. Visit our treatment page to start.

    Frequently Asked Questions

    Which GLP-1 has the fewest side effects?

    Tirzepatide has the lowest discontinuation rate due to side effects in clinical trials, making it the best-tolerated option overall. However, individual responses vary. Some patients tolerate semaglutide perfectly but struggle with tirzepatide, and vice versa.

    Do side effects get worse with stronger medications?

    Not necessarily. Side effects are primarily dose-dependent (higher doses = more side effects) rather than medication-dependent. Because all three medications start at low doses and titrate up, the side effect experience is similar during the early weeks regardless of which medication you choose.

    Can I switch to avoid specific side effects?

    Yes. If you have persistent side effects on one medication, switching to another GLP-1 may resolve them. The different receptor profiles mean your body may respond differently to each medication.

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    Related Reading